PROFESSIONAL INFORMATION FOR AMORTIVO 5 %

SCHEDULING STATUS

S1

1. NAME OF THE MEDICINE

AMORTIVO 5 % nail lacquer.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 mL solution contains 50 mg amorolfine (as hydrochloride).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Medicated nail lacquer.
A clear, colourless to pale yellow solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Onychomycoses caused by dermatophytes, yeasts and moulds.
Only little experience is available in cases where the nail matrix was involved.

4.2 Posology and method of administration

Onychomycoses

Nail lacquer: To be applied to affected finger- or toenails once or twice weekly.
The patient should apply the nail lacquer as follows:

1. Before the first application of AMORTIVO 5 %, it is essential that the affected areas of nail (particularly the nail surfaces) should be filed down as thoroughly as possible using a disposable nail file supplied. The surface of the nail should then be cleansed and degreased using an alcohol-soaked swab (as supplied).
   Before repeating application of AMORTIVO 5 %, the affected nails should be filed down again as required and must at all times first be cleansed with an alcohol-soaked swab to remove any remaining lacquer.
   Caution: Nail files used for affected nails must not be used for healthy nails.
2. With the applicator supplied, apply the nail lacquer to the entire surface of the affected nails and allow it to dry for approximately 3 – 5 minutes.
   For each nail to be treated, dip the applicator into the nail lacquer without wiping off any of the lacquer on the bottle neck.
   After use, clean the applicator with the same pre-soaked swab used before for nail cleansing.
   Keep the bottle tightly closed.
3. When working with organic solvents (thinners, white spirit, etc.) wear impermeable gloves in order to protect the AMORTIVO 5 % on the nails.

Treatment should be continued without interruption until the nail is regenerated and the affected areas are finally cured. The required duration of treatment depends essentially on intensity and localisation of the infection and on growth rate of the nails, but in general, it is six months for fingernails and nine to twelve months for toenails.

Clinical experience indicates that cure is achieved after six months in approximately 50 % of distal onychomycosis cases in which less than 80 % of the nail surface was affected. Mycological cure was achieved in 60 – 80 % of cases.

4.3 Contraindications

- Hypersensitivity to the amorolfine or to any of the excipients listed in section 6.1.
- No experience exists with pregnancy and nursing and the use of AMORTIVO 5 % should therefore be avoided during pregnancy and lactation (see section 4.6).
- Owing to lack of clinical experience to date, children should not be treated with AMORTIVO 5 %.

4.4 Special warnings and precautions for use

- AMORTIVO 5 % should not be applied on the skin around the nail.
- Avoid contact of the lacquer with eyes, ears and mucous membranes.
- Use of cosmetic lacquers or artificial nails should be avoided during treatment with AMORTIVO 5 %.
- After applying AMORTIVO 5 %, an interval of at least 10 minutes should be allowed before application of any cosmetic nail lacquer. Before repeat application of AMORTIVO 5 %, the cosmetic nail lacquer should be removed carefully.
- Wear impermeable gloves when organic solvents are handled, otherwise AMORTIVO 5 % will be removed.
- A systemic or local allergic reaction could possibly occur after use of this AMORTIVO 5 %. If this happens, stop the application of AMORTIVO 5 % immediately and seek medical advice.
  Remove AMORTIVO 5 % carefully by using a nail remover solution. Do not reapply AMORTIVO 5 % (see section 4.3).

Paediatric population

Owing to the lack of clinical experience available to date, children should not be treated with AMORTIVO 5 %.

4.5 Interaction with other medicines and other forms of interaction

No interaction studies have been performed.
Use of artificial nails should be avoided during treatment.

4.6 Fertility, pregnancy and lactation

Pregnancy

No experience exists with pregnancy and the use of AMORTIVO 5 % should therefore be avoided during pregnancy.

Breastfeeding

No experience exists with nursing and the use of AMORTIVO 5 % should therefore be avoided during breastfeeding.

Fertility

No experience exists with fertility and the use of AMORTIVO 5 % should therefore be avoided during pregnancy.

4.7 Effects on ability to drive and use machines
The effects of AMORTIVO 5 % on the ability to operate a vehicle or other heavy machinery is not relevant.

4.8 Undesirable effects

Immune system disorders
Frequency unknown: Hypersensitivity (systemic allergic reaction).

Skin and subcutaneous tissue disorders
Frequent: Nail disorder, nail discolouration, onychoclasis (broken nails), onychorrhexis (brittle nails). These reactions can also be linked to the onychomycosis itself.

Less frequent: Burning sensation of the skin.

Unknown frequency: Erythema, pruritus, urticaria, blisters, contact dermatitis.

Paediatric population
Owing to the lack of clinical experience available to date, children (particularly young children and infants) should not be treated with AMORTIVO 5 %.

Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of AMORTIVO 5 % is important. It allows continued monitoring of the benefit/risk balance of AMORTIVO 5 %. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the "**Adverse Drug Reactions Reporting Form**", found online under SAHPRA's publications: https://www.sahpra.org.za/Publications/Index/8.

4.9 Overdose
No systemic signs of overdose are expected following topical application of AMORTIVO 5 % nail lacquer.
In case of accidental oral ingestion, treatment should be symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Category and class: A 13.8.2 Fungicides.
Pharmacotherapeutic group: Other antifungals for topical use.
ATC code: D01AE16.

Amorolfine is a topical antimycotic. Amorolfine has both *in vitro* fungicidal and fungistatic properties based on an alteration of the fungal cell membrane targeted primarily on sterol biosynthesis. The ergosterol content is reduced, and at the same time unusual sterically nonplanar sterols accumulate.

Amorolfine has a broad spectrum of action *in vitro* against:
yeasts: **Candida, Malassezia* or *Pityrosporum*, *Cryptococcus*
dermatophytes: **Trichophyton*, **Microsporum*, **Epidermophyton*
moulds: **Hendersonula*, **Alternaria*, **Scopulariopsis*, *Scytalidium*
dematiacea: **Cladosporium*, *Fonsecaea*, *Wangiella* [* in onychomycosis]
dimorphic fungi: *Coccidioides immites*, *Histoplasma capsulatum*, *Sporothrix schenckil*.

With the exception of *Actinomyces*, bacteria are not sensitive to amorolfine.
Propionibacterium acnes is only slightly sensitive.

5.2 Pharmacokinetic properties
Amorolfine from nail lacquer penetrates and diffuses through the nail plate and effective concentrations accumulate in the nail bed where access to fungi is critical.
Systemic absorption of the active ingredient is very low with this type of application.
Following prolonged use of amorolfine there is no indication of amorolfine accumulation in the body.

Paediatric population
No data available.

5.3 Preclinical safety data
None stated.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
n-Butyl acetate
Ethyl acetate
Ethanol, anhydrous (55,4 %)
Eudragit RL 100 (ammonio methacrylate copolymer type A)
Triacetin.

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
3 years.

6.4 Special precautions for storage
Store at or below 25 °C.
Protect from heat.
Keep the bottle upright and tightly closed.

6.5 Nature and contents of container
2,5 mL solution filled in amber glass (Type I or Type III) bottle with an HDPE cap with PTFE liner and tamper-evident ring.
Supplied with 30 swabs (alcohol wipes), 30 nail files and 10 LDPE applicators.

6.6 Special precautions for disposal and other handling
No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION
Activo Health (Pty) Ltd
Block B
Arena Office Park
272 West Avenue
Centurion
0157

8. REGISTRATION NUMBER
55/13.8.2/0751

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31 January 2023

10. DATE OF REVISION OF THE TEXT
To be allocated.